BIOLASE (NASDAQ:BIOL) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of BIOLASE (NASDAQ:BIOL) in a research report report published on Wednesday. The brokerage issued a sell rating on the medical technology company’s stock.

Separately, Benchmark reissued a “speculative buy” rating and issued a $0.40 price target on shares of BIOLASE in a research note on Wednesday, October 2nd.

BIOLASE Stock Down 4.3 %

NASDAQ:BIOL opened at $0.01 on Wednesday. The business’s 50-day moving average price is $0.01 and its 200 day moving average price is $0.04. The firm has a market cap of $300,663.00, a P/E ratio of 0.00 and a beta of 0.67. BIOLASE has a 52-week low of $0.02 and a 52-week high of $1.94.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.